# A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

> **NCT01787383** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 200 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol mebutate gel 0.05 %
- **DRUG:** Ingenol mebutate gel 0.015 %

## Key facts

- **NCT ID:** NCT01787383
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787383, "A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01787383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*